Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUAK1 | O60285 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 10/20 | 0.42 |
| ▸ | JAK2 | O60674 | 10/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | BRD2 | P25440 | 3/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756769 | 0.91 | NUAK1 (0.54) | NUAK1CDK2BRD4JAK2JAK1 | |
| SCHEMBL13756799 | 0.86 | CDK2 (0.53) | NUAK1CDK2CCNT1CCNE1CDK9 | |
| SCHEMBL13756697 | 0.86 | CSF1R (0.41) | CDK2BRD4JAK2EPHX2CCNA2 | |
| SCHEMBL13756843 | 0.85 | NUAK1 (0.47) | NUAK1CDK2CCNE1BRD4JAK2 | |
| SCHEMBL13756842 | 0.83 | NUAK1 (0.45) | NUAK1CDK2JAK2JAK1JAK3 | |
| SCHEMBL1654957 | 0.82 | JAK2 (0.59) | BRD4JAK2JAK1BRD2BRD3 | |
| SCHEMBL13756691 | 0.81 | AURKA (0.54) | BRD4JAK2JAK1JAK3CDK4 | |
| SCHEMBL13756756 | 0.81 | PTGS2 (0.48) | CDK2CCNT1CCNE1CDK9BRD4 | |
| SCHEMBL13756800 | 0.80 | CDK2 (0.46) | CDK2CCNE1BRD4JAK2CCNB2 | |
| SCHEMBL13756832 | 0.79 | JAK2 (0.56) | CDK2BRD4JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | NUAK1 488/4885CDK2 77/4885CCNT1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.